[PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB]
| Autor: | Junichi Ota, Kazuhiro Namura, Masatoshi Moriyama, Atsushi Fujikawa, Takuto Sawada, Shinji Otake |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Indoles Lung Neoplasms Urology medicine.medical_treatment Antineoplastic Agents Renal cell carcinoma medicine Carcinoma Sunitinib Humans Pyrroles Everolimus Carcinoma Renal Cell Lung business.industry Remission Induction Middle Aged medicine.disease Nephrectomy Kidney Neoplasms medicine.anatomical_structure Drug Resistance Neoplasm Clear cell carcinoma Radiology business Tomography X-Ray Computed Progressive disease medicine.drug |
| Zdroj: | Nihon Hinyokika Gakkai zasshi. The japanese journal of urology. 106(1) |
| ISSN: | 0021-5287 |
| Popis: | A 55-year-old man was referred to our hospital because of a tumor in his right kidney. A Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT) scan revealed strong abnormal uptake by the tumor in the right kidney and a nodule in the right lung. The patient was diagnosed with stage IV renal cell cancer, for which he underwent transperitoneal nephrectomy. Pathological diagnosis revealed the tumor to be a renal cell carcinoma (clear cell carcinoma, G2, pT3a, v (+), INF-β). Sunitinib was administered because of the occurrence of multiple lung metastases; however, the therapeutic effect was insufficient, and progressive disease was observed on a CT scan. Therefore, everolimus was immediately administered as a second-line therapeutic agent. After treatment, the lung metastases reduced in size, as observed on a CT scan, and partial response continued for 1 year after therapy. One metastatic lesion persisted in the right lung; therefore, he underwent right upper lobe resection after discontinuing everolimus administration. No viable tumor cells were observed on pathological diagnosis, and the patient achieved pathological complete response. 3 month after discontinuing everolimus administration, no metastatic lesions have been observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|